Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Oct 14

PMID 37833968

Authors

Yiyi Huang

Yi-Fung Chau

Hua Bai

Xinyu Wu

Jianchun Duan

Affiliations

Soon will be listed here.

Abstract

Outcome improvement in patients with driver-gene-negative advanced non-small cell lung cancer (NSCLC) has been significantly enhanced through targeting the immune system, specifically the PD-L1/PD-1 axis. Nevertheless, only a subset of patients with advanced NSCLC may derive benefits from immuno-monotherapy or immunotherapy combined with chemotherapy. Hence, in order to identify patients who will gain the maximum advantage from immunotherapy, it is crucial to investigate predictive biomarkers. This review provides a summary of the currently identified biomarkers associated with the extent of benefit from immuno-monotherapy or immunotherapy combined with chemotherapy in patients with advanced NSCLC. These biomarkers can be categorized into three groups: tumor-related, tumor-microenvironment-related, and host-factor-related.Tumor-related factors include PD-L1 expression, tumor mutational burden and specific genetic mutations, while tumor-microenvironment-related factors include extracellular vesicles and T-cell receptors, and host-related factors include systemic inflammation, circulating fatty acid profile, and the microbiome.

Citing Articles

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Rother C, John T, Wong A Front Oncol. 2025; 14:1489977.

PMID: 39749035 PMC: 11693593. DOI: 10.3389/fonc.2024.1489977.

Predicting immunotherapy-related adverse events in late-stage non-small cell lung cancer with KARS G12C mutation treated with PD-1 inhibitors through combined assessment of LCP1 and ADPGK expression levels.

Chen L, Xu C, Ren W, Yu L, Tang T Am J Cancer Res. 2024; 14(10):4803-4816.

PMID: 39553202 PMC: 11560835. DOI: 10.62347/MWLI5585.

Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer.

Ufimtseva E, Gileva M, Kostenko R, Kozlov V, Gulyaeva L Cancers (Basel). 2024; 16(16).

PMID: 39199657 PMC: 11352364. DOI: 10.3390/cancers16162886.

Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center.

Coelho J, Romao R, Sousa M, Azevedo S, Fidalgo P, Araujo A Curr Oncol. 2024; 31(2):1113-1128.

PMID: 38392077 PMC: 10887781. DOI: 10.3390/curroncol31020083.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y . Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial. J Thorac Oncol. 2022; 18(1):93-105. DOI: 10.1016/j.jtho.2022.09.217. View

Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G . Identification of Deleterious Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC. Clin Cancer Res. 2020; 26(14):3649-3661. DOI: 10.1158/1078-0432.CCR-19-3976. View

Mirji G, Worth A, Bhat S, El Sayed M, Kannan T, Goldman A . The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci Immunol. 2022; 7(75):eabn0704. PMC: 9925043. DOI: 10.1126/sciimmunol.abn0704. View

Wang Z, Duan J, Wang G, Zhao J, Xu J, Han J . Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. J Thorac Oncol. 2019; 15(4):556-567. DOI: 10.1016/j.jtho.2019.12.001. View

Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X . Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. J Thorac Oncol. 2021; 16(9):1512-1522. DOI: 10.1016/j.jtho.2021.05.005. View

Novello S, Kowalski D, Luft A, Gumus M, Vicente D, Mazieres J . Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023; 41(11):1999-2006. PMC: 10082300. DOI: 10.1200/JCO.22.01990. View

Oh S, Kim S, Keam B, Kim T, Kim D, Heo D . Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021; 11(1):19712. PMC: 8492653. DOI: 10.1038/s41598-021-99311-y. View

Li X, Wenes M, Romero P, Huang S, Fendt S, Ho P . Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019; 16(7):425-441. DOI: 10.1038/s41571-019-0203-7. View

10.

Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S . Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 2022; 171:56-60. DOI: 10.1016/j.lungcan.2022.07.013. View

11.

Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A . Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020; 8(2). PMC: 7537334. DOI: 10.1136/jitc-2020-000678. View

12.

Herbst R, Garon E, Kim D, Cho B, Perez-Gracia J, Han J . Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020; 38(14):1580-1590. DOI: 10.1200/JCO.19.02446. View

13.

Song M, Lee D, Chun K, Kim E . The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism. Int J Mol Sci. 2021; 22(9). PMC: 8122702. DOI: 10.3390/ijms22094376. View

14.

Lee P, Wu C, Hung Y, Lee C, Chi C, Lee I . Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022; 10(6). PMC: 9226985. DOI: 10.1136/jitc-2022-004779. View

15.

Li Z, Zhou Q, Wang Q, Wang H, Yue W . EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. BMC Pulm Med. 2022; 22(1):356. PMC: 9487080. DOI: 10.1186/s12890-022-02161-1. View

16.

Wang Y, Cao S, Li J, Zhang Y, Ling X, Zhang L . The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy. Adv Med Sci. 2023; 68(1):86-93. DOI: 10.1016/j.advms.2023.01.003. View

17.

Zhu J, Thompson C . Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019; 20(7):436-450. PMC: 6592760. DOI: 10.1038/s41580-019-0123-5. View

18.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

19.

Hosgood H, Cai Q, Hua X, Long J, Shi J, Wan Y . Variation in oral microbiome is associated with future risk of lung cancer among never-smokers. Thorax. 2020; 76(3):256-263. PMC: 8513501. DOI: 10.1136/thoraxjnl-2020-215542. View

20.

Chen X, Fang L, Zhu Y, Bao Z, Wang Q, Liu R . Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunol Immunother. 2021; 70(12):3513-3524. PMC: 10991091. DOI: 10.1007/s00262-021-02943-2. View